Home › NDC Lookup › Ingredients › Pentosan Polysulfate Sodium › 50458-0098-01
Elmiron Pentosan Polysulfate Sodium 100 mg Capsule, Gelatin Coated, 100-count — NDC 50458-0098-01 package photo
Label image from the product's FDA listing (DailyMed) — may show a different pack size or an older label revision.

Elmiron Pentosan Polysulfate Sodium 100 mg Capsule, Gelatin Coated, 100-count — NDC 50458-098-01 (Billing 50458-0098-01)

by Janssen Pharmaceuticals, Inc. · 100 CAPSULE, GELATIN COATED in 1 BOTTLE

This is a package of 100 capsules of Elmiron Pentosan Polysulfate Sodium 100 mg Capsule, Gelatin Coated from Janssen Pharmaceuticals, Inc., first listed with the FDA Sep 1996 and currently FDA-listed; retail pharmacies pay about $12.09 per capsule (NADAC). It is this product's only package size.

NDC 50458-0098-01
🏷️ FDA NDC (as labeled) 50458-098-01 billing pads the product segment with a zero
Rx only Brand FDA-listed Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Nov 19, 2026 · this listing last changed Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

NDC database record

One package, one record: these facts belong to NDC 50458-098-01 alone.

Record
FDA NDC Directory package listing · Human prescription drug
Code segments
50458 labeler · 098 product · 01 package
Package marketed since
Sep 26, 1996
Sample package
No — commercial package
Listing certified through
Dec 31, 2026
Billing quantity
100 EA per package
Barcode (UPC)
0350458098013
Medicaid fills, this package
10,327 prescriptions in the last four reported quarters
FDA record last changed
Jul 24, 2026

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 50458-098-01
Product NDC 50458-098
11-digit billing NDC 50458009801
NCPDP billing unit EA — each (per item)
RxCUI 199498, 211140
UNII 914032762Y
UPC 0350458098013
Application # NDA020193
SPL Set ID f0ba651e-3d8a-11df-8fbe-119855d89593
Established class (EPC) Glycosaminoglycan
Chemical class Glycosaminoglycans
DEA schedule Non-controlled
Marketing category NDA
Marketing status FDA-listed
FDA listing status Listed (active directory)
Marketing start 1996-09-26
Route ORAL
Dosage form CAPSULE, GELATIN COATED
Substance PENTOSAN POLYSULFATE SODIUM

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GPI-14 56500060100110
GPI class Elmiron
GCN Seq No 021175
GCN 41229
HICL code 008734
Ingredient (HICL) Pentosan Polysulfate Sodium
HIC1 code R
Therapeutic class — broad (HIC1) Kidney/Urinary Tract
HIC2 code R5
Therapeutic class — intermediate (HIC2) Urinary Tract Anesthetic/Analgesic Agents
HIC3 code R5B
Therapeutic class — specific (HIC3) Urinary Tract Analgesic Agents
AHFS code 91:04.12.00
AHFS class Chemotherapy Antidotes/Protectants
FDB label name ELMIRON 100 MG CAPSULE
FDB brand name Elmiron
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 021175
  • GCN: 41229
  • GPI-14 (Medi-Span): 56500060100110
  • HICL (First Databank): 008734
  • AHFS class code: 91:04.12.00
  • RxCUI (RxNorm): 199498
Why two NDCs? The FDA registers this code as 50458-098-01 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 50458-0098-01. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

RxNorm drug class

This medicine belongs to the Glycosaminoglycan class.

Pharmacologic class Glycosaminoglycan
Drug family (ATC) Heparins or heparinoids for topical use, Other urologicals
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

Clinical

Label name ELMIRON 100 MG CAPSULE Ingredient Pentosan Polysulfate Sodium
📖 What it is MedlinePlus · NLM

Pentosan polysulfate is used to relieve bladder pain and discomfort related to interstitial cystitis, a disease that causes swelling and scarring of the bladder wall. Pentosan polysulfate is similar to a class of medications called low molecular weight heparins. It works by preventing irritation of the bladder walls.

Read the full MedlinePlus article ↗
📗 Our plain-language guide HelloPharmacist
  • It relieves bladder pain or discomfort from interstitial cystitis. This is a long-term bladder condition. It is taken as a capsule by mouth.
  • Take one capsule three times a day with water. Take it at least 1 hour before a meal or 2 hours after. Follow your prescriber's directions.
  • Your prescriber will check your progress after about 3 months. If you are improving and not having limiting side effects, it may continue another 3 months. The label says the value...
  • Yes. Long-term use has been linked to changes in the retina that may cause trouble reading, slow adjustment to dim light, or blurry vision. These changes may be irreversible. Get r...
📖 Read our full Pentosan Polysulfate guide →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eaPer package
Retail pharmacies payNADAC · weekly $12.088 $1,208.83 / 100 capsules
Medicaid paysCMS SDUD · 12 mo $11.61 $1,161.03 / 100 capsules
Medicare drug plans payPart D · Q2 2026 $12.08 $1,208.33 / 100 capsules
NADAC price history (per ea) — tap or hover for the price & month
May 2024 Dec 2024 Nov 2025 Nov 2026 $12.108 $10.841
▲ Up 11% over the last 24 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Marketing startMarketing endStatus
50458-0098-01 You're viewing this Main listing 100 CAPSULE, GELATIN COATED in 1 BOTTLE 1996-09-26 — Active

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Elmiron 100 mgthis 50458-0098-01 Janssen 100 capsules $12.088 — Availability likely —
About this product: this is the brand-name version. We did not find an FDA-approved generic match for this exact strength, form and route.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
1996
Listed with the FDA since
Sep 1996
📍
2026
Currently FDA-listed
30 years listed
🔒
·
No generic listed yet
brand only
ℹ️No FDA-approved generic found

We did not find an FDA-approved generic match for this exact strength, form and route.

When could a generic Elmiron arrive?

No date yet

The patents are not the problem. A generic still needs FDA sign-off, and that is when it is expected.

See the full forecast for generic Elmiron →
Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

What it looks like

Color white
ShapeCapsule
ImprintBNP7600
Size18 mm
ScoringNot scored
One label can cover several strengths, so colors may be combined — always confirm a loose pill against the dispensed prescription label or a pharmacist.
Where does this data come from?
Physical description (imprint, shape, color, scoring, coating) from this product’s FDA Structured Product Labeling (SPL), mirrored from DailyMed / openFDA.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

🧪 Avoiding an ingredient? See Pentosan Polysulfate inactive ingredients by manufacturer: every current product's list side by side, so you can ask your pharmacy for the version that does not list it.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII LMI26O6933
    Alumina is a white powder form of aluminum oxide. It's used as a filler to add bulk to tablets and capsules, and sometimes as a thickening or anti-caking agent in powdered formulations.
  • UNII 8PJ61P6TS3
    Butyl alcohol is a clear liquid organic solvent derived from petroleum or natural sources. In medicines, it helps dissolve active ingredients and serves as a solvent in liquid formulations and some topical products.
  • UNII 35SW5USQ3G
    A synthetic yellow dye used to color medicines. It helps make tablets, capsules, and liquids visually distinct so patients can easily identify their medication.
  • UNII H3R47K3TBD
    FD&C Blue No. 1 is a synthetic blue dye approved for use in foods and medicines. It serves as a colorant to give the medication its distinctive appearance and help with product identification.
  • UNII L06K8R7DQK
    A synthetic blue dye approved by the FDA for use in medications and foods. It serves as a colorant to make pills and liquids visually distinct and easier to identify.
  • UNII WZB9127XOA
    A synthetic red dye used to color medications and make them easier to identify. It serves as a colorant in tablets, capsules, and liquid formulations.
  • UNII XM0M87F357
    A dark iron oxide compound that gives medicines their black or dark color. It's used as a colorant in tablets and capsules to help identify the product and make it visually distinctive.
  • UNII 70097M6I30
    Magnesium stearate is a salt made from magnesium and stearic acid, a fatty substance. It's used in tablets and capsules as a lubricant and glidant to help ingredients flow smoothly during manufacturing and prevent sticking.
  • UNII OP1R32D61U
    Microcrystalline cellulose is a purified form of cellulose, a natural fiber from plant sources. It acts as a binder and filler in tablets and capsules, helping hold ingredients together and give the medicine its shape and size.
  • UNII 6DC9Q167V3
    Propylene glycol is a clear liquid derived from petroleum or vegetable sources. It acts as a solvent, humectant, and preservative in medicines, helping dissolve active ingredients and maintain product stability.
  • UNII 15FIX9V2JP
    Titanium dioxide is a bright white mineral powder commonly used as a colorant and opacifying agent. It makes pills and tablets white or lighter in color and helps make coatings non-transparent.

11 inactive ingredients listed in the exact product block matched to this NDC.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerJanssen Pharmaceuticals, Inc.
Application holderJANSSEN PHARMACEUTICALS INC
FDA applicationNDA020193 (NDA)
Labeler code50458
First marketedSep 1996
Product typeHuman Prescription Drug
Portfolio59 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Very long sections are excerpted here and marked; the full text is on DailyMed (linked in the sources below). Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage 22 words ▾

INDICATIONS AND USAGE ELMIRON ® (pentosan polysulfate sodium) is indicated for the relief of bladder pain or discomfort associated with interstitial cystitis.

⏱️ Dosage and Administration 93 words ▾

DOSAGE AND ADMINISTRATION The recommended dose of ELMIRON ® is 300 mg/day taken as one 100 mg capsule orally three times daily. The capsules should be taken with water at least 1 hour before meals or 2 hours after meals. Patients receiving ELMIRON ® should be reassessed after 3 months.

If improvement has not occurred and if limiting adverse events are not present, ELMIRON ® may be continued for another 3 months. The clinical value and risks of continued treatment in patients whose pain has not improved by 6 months is not known.

⛔ Contraindications 18 words ▾

CONTRAINDICATIONS ELMIRON ® is contraindicated in patients with known hypersensitivity to the drug, structurally related compounds, or excipients.

⚠️ Warnings ~1 min read ▾

WARNINGS Retinal Pigmentary Changes Pigmentary changes in the retina, reported in the literature as pigmentary maculopathy, have been identified with long-term use of ELMIRON ® (see ADVERSE REACTIONS ). Although most of these cases occurred after 3 years of use or longer, cases have been seen with a shorter duration of use. While the etiology is unclear, cumulative dose appears to be a risk factor.

Visual symptoms in the reported cases included difficulty reading, slow adjustment to low or reduced light environments, and blurred vision. The visual consequences of these pigmentary changes are not fully characterized. Caution should be used in patients with retinal pigment changes from other causes in which examination findings may confound the appropriate diagnosis, follow-up, and treatment.

Detailed ophthalmologic history should be obtained in all patients prior to starting treatment with ELMIRON ® . If there is a family history of hereditary pattern dystrophy, genetic testing should be considered. For patients with pre-existing ophthalmologic conditions, a comprehensive baseline retinal examination (including color fundoscopic photography, ocular coherence tomography (OCT), and auto-fluorescence imaging) is recommended prior to starting therapy.

A baseline retinal examination (including OCT and auto-fluorescence imaging) is suggested for all patients within six months of initiating treatment and periodically while continuing treatment. If pigmentary changes in the retina develop, then risks and benefits of continuing treatment should be re-evaluated, since these changes may be irreversible. Follow-up retinal examinations should be continued given that retinal and vision changes may progress even after cessation of treatment.

🤒 Adverse Reactions ~3 min read ▾

ADVERSE REACTIONS ELMIRON ® was evaluated in clinical trials in a total of 2627 patients (2343 women, 262 men, 22 unknown) with a mean age of 47 [range 18 to 88 with 581 (22%) over 60 years of age]. Of the 2627 patients, 128 patients were in a 3-month trial and the remaining 2499 patients were in a long-term, unblinded trial. Deaths occurred in 6/2627 (0.2%) patients who received the drug over a period of 3 to 75 months.

The deaths appear to be related to other concurrent illnesses or procedures, except in one patient for whom the cause was not known. Serious adverse events occurred in 33/2627 (1.3%) patients. Two patients had severe abdominal pain or diarrhea and dehydration that required hospitalization.

Because there was not a control group of patients with interstitial cystitis who were concurrently evaluated, it is difficult to determine which events are associated with ELMIRON ® and which events are associated with concurrent illness, medicine, or other factors. Adverse Experience in Placebo-Controlled Clinical Trials of ELMIRON ® 100 mg Three Times a Day for 3 Months Body System/Adverse Experience ELMIRON ® n=128 Placebo n=130 CNS Overall Number of Patients Within a body system, the individual events do not sum to equal overall number of patients because a patient may have more than one event.

3 5 Insomnia 1 0 Headache 1 3 Severe Emotional Lability/Depression 2 1 Nystagmus/Dizziness 1 1 Hyperkinesia 1 1 GI Overall Number of Patients 7 7 Nausea 3 3 Diarrhea 3 6 Dyspepsia 1 0 Jaundice 0 1 Vomiting 0 2 Skin/Allergic Overall Number of Patients 2 4 Rash 0 2 Pruritus 0 2 Lacrimation 1 1 Rhinitis 1 1 Increased Sweating 1 0 Other Overall Number of Patients 1 3 Amenorrhea 0 1 Arthralgia 0 1 Vaginitis 1 1 Total Events 17 27 Total Number of Patients Reporting Adverse Events 13 19 The adverse events described below were reported in an unblinded clinical trial of 2499 interstitial cystitis patients treated with ELMIRON ® .

Of the original 2499 patients, 1192 (48%) received ELMIRON ® for 3 months; 892 (36%) received ELMIRON ® for 6 months; and 598 (24%) received ELMIRON ® for one year, 355 (14%) received ELMIRON ® for 2 years, and 145 (6%) for 4 years. Frequency (1 to 4%): Alopecia (4%), diarrhea (4%), nausea (4%), headache (3%), rash (3%), dyspepsia (2%), abdominal pain (2%), liver function abnormalities (1%), dizziness (1%). Frequency (≤ 1%): Digestive: Vomiting, mouth ulcer, colitis, esophagitis, gastritis, flatulence, constipation, anorexia, gum hemorrhage.

Hematologic: Anemia, ecchymosis, increased prothrombin time, increased partial thromboplastin time, leukopenia, thrombocytopenia. Hypersensitive Reactions: Allergic reaction, photosensitivity. Respiratory System: Pharyngitis, rhinitis, epistaxis, dyspnea.

Skin and Appendages: Pruritus, urticaria. Special Senses: Conjunctivitis, tinnitus, optic neuritis, amblyopia, retinal hemorrhage. Post-Marketing Experience The following adverse reactions have been identified during post approval use of pentosan polysulfate sodium; because these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: pigmentary changes in the retina (see WARNINGS ).

Rectal Hemorrhage ELMIRON ® was evaluated in a randomized, double-blind, parallel group, Phase 4 study conducted in 380 patients with interstitial cystitis dosed for 32 weeks. At a daily dose of 300 mg (n=128), rectal hemorrhage was reported as an adverse event in 6.3% of patients. The severity of the events was described as "mild" in most patients.

Patients in that study who were administered ELMIRON ® 900 mg daily, a dose higher than the approved dose, experienced a higher incidence of rectal hemorrhage, 15%. Liver Function Abnormality A randomized, double-blind, parallel group, Phase 2 study was conducted in 100 men (51 ELMIRON ® and 49 placebo) dosed for 16 weeks. At a daily dose of 900 mg, a dose higher than th… [Excerpted — this section continues on DailyMed.]

🔄 Drug Interactions 84 words ▾

Drug-Drug Interactions In a study in which healthy subjects received pentosan polysulfate sodium 100 mg capsule or placebo every 8 hours for 7 days, and were titrated with warfarin to an INR of 1.4 to 1.8, the pharmacokinetic parameters of R-warfarin and S-warfarin were similar in the absence and presence of pentosan polysulfate sodium. INR for warfarin + placebo and warfarin + pentosan polysulfate sodium were comparable. See also PRECAUTIONS on the use of ELMIRON ® in patients receiving other therapies with anticoagulant effects.

🤰 Pregnancy 119 words ▾

Pregnancy Reproduction studies have been performed in mice and rats with intravenous daily doses of 15 mg/kg, and in rabbits with 7.5 mg/kg. These doses are 0.42 and 0.14 times the daily oral human doses of ELMIRON ® when normalized to body surface area. These studies did not reveal evidence of impaired fertility or harm to the fetus from ELMIRON ® .

Direct in vitro bathing of cultured mouse embryos with pentosan polysulfate sodium (PPS) at a concentration of 1 mg/mL may cause reversible limb bud abnormalities. Adequate and well-controlled studies have not been performed in pregnant women. Because animal studies are not always predictive of human response, this drug should be used in pregnancy only if clearly needed.

🧒 Pediatric Use 18 words ▾

Pediatric Use Safety and effectiveness in pediatric patients below the age of 16 years have not been established.

🆘 Overdosage 143 words ▾

OVERDOSAGE Overdose has not been reported. Based upon the pharmacodynamics of the drug, toxicity is likely to be reflected as anticoagulation, bleeding, thrombocytopenia, liver function abnormalities, and gastric distress (see CLINICAL PHARMACOLOGY and PRECAUTIONS ). At a daily dose of 900 mg for 32 weeks (n=127) in a clinical trial, rectal hemorrhage was reported as an adverse event in 15% of patients.

At a daily dose of ELMIRON ® 900 mg for 16 weeks in a clinical trial that enrolled 51 patients in the ELMIRON ® group and 49 in the placebo group, elevated liver function tests were reported as an adverse event in 11.8% of patients in the ELMIRON ® group and 2% of patients in the placebo group. In the event of acute overdosage, the patient should be given gastric lavage if possible, carefully observed and given symptomatic and supportive treatment.

🧬 Clinical Pharmacology ~2 min read ▾

CLINICAL PHARMACOLOGY General Pentosan polysulfate sodium is a low molecular weight heparin-like compound. It has anticoagulant and fibrinolytic effects. The mechanism of action of pentosan polysulfate sodium in interstitial cystitis is not known.

Pharmacokinetics Absorption In a clinical pharmacology study in which healthy female volunteers received a single oral 300 or 450 mg dose of pentosan polysulfate sodium containing radiolabeled drug as a solution under fasted conditions, maximal levels of plasma radioactivity were seen approximately at a median of 2 hours (range 0.6-120 hours) after dosing. Based on urinary excretion of radioactivity, a mean of approximately 6% of a radiolabeled oral dose of pentosan polysulfate sodium is absorbed and reaches the systemic circulation.

Food Effects: In clinical trials, ELMIRON ® was administered with water 1 hour before or 2 hours after meals; the effect of food on absorption of pentosan polysulfate sodium is not known. Distribution Preclinical studies with parenterally administered radiolabeled pentosan polysulfate sodium showed distribution to the uroepithelium of the genitourinary tract with lesser amounts found in the liver, spleen, lung, skin, periosteum, and bone marrow. Erythrocyte penetration is low in animals.

Metabolism The fraction of pentosan polysulfate sodium that is absorbed is metabolized by partial desulfation in the liver and spleen, and by partial depolymerization in the kidney to a large number of metabolites. Both the desulfation and depolymerization can be saturated with continued dosing. Excretion Following administration of an oral solution of a 300 or 450 mg dose of pentosan polysulfate sodium containing radiolabeled drug to groups of healthy subjects, plasma radioactivity declined with mean half-lives of 27 and 20 hours, respectively.

A large proportion of the orally administered dose of pentosan polysulfate sodium (mean 84% in the 300 mg group and 58% in the 450 mg group) is excreted in feces as unchanged drug. A mean of 6% of an oral dose is excreted in the urine, mostly as desulfated and depolymerized metabolites. Only a small fraction of the administered dose (mean 0.14%) is recovered as intact drug in urine.

Special Populations The pharmacokinetics of pentosan polysulfate sodium has not been studied in geriatric patients or in patients with hepatic or renal impairment. See also PRECAUTIONS-Hepatic Insufficiency . Drug-Drug Interactions In a study in which healthy subjects received pentosan polysulfate sodium 100 mg capsule or placebo every 8 hours for 7 days, and were titrated with warfarin to an INR of 1.4 to 1.8, the pharmacokinetic parameters of R-warfarin and S-warfarin were similar in the absence and presence of pentosan polysulfate sodium.

INR for warfarin + placebo and warfarin + pentosan polysulfate sodium were comparable. See also PRECAUTIONS on the use of ELMIRON ® in patients receiving other therapies with anticoagulant effects. Pharmacodynamics The mechanism by which pentosan polysulfate sodium achieves its effects in patients is unknown.

In preliminary clinical models, pentosan polysulfate sodium adhered to the bladder wall mucosal membrane. The drug may act as a buffer to control cell permeability preventing irritating solutes in the urine from reaching the cells.

📦 How Supplied / Storage and Handling 61 words ▾

HOW SUPPLIED ELMIRON ® is supplied in white opaque hard gelatin capsules imprinted "BNP7600" containing 100 mg pentosan polysulfate sodium. Supplied in bottles of 100 capsules. NDC NUMBER 50458-098-01 Storage Store at 20 °C to 25 °C (68 °F to 77 °F); excursions permitted to 15 °C to 30 °C (59 °F to 86 °F). Keep out of reach of children.

📦 Storage and Handling 32 words ▾

Storage Store at 20 °C to 25 °C (68 °F to 77 °F); excursions permitted to 15 °C to 30 °C (59 °F to 86 °F). Keep out of reach of children.

📋 Description 124 words ▾

DESCRIPTION Pentosan polysulfate sodium is a semi-synthetically produced heparin-like macromolecular carbohydrate derivative, which chemically and structurally resembles glycosaminoglycans. It is a white odorless powder, slightly hygroscopic and soluble in water to 50% at pH 6. It has a molecular weight of 4000 to 6000 Dalton with the following structural formula: ELMIRON ® is supplied in white, opaque hard gelatin capsules containing 100 mg pentosan polysulfate sodium, microcrystalline cellulose, and magnesium stearate.

It also contains pharmaceutical glaze (modified) in SD-45, synthetic black iron oxide, FD&C Blue No. 2 aluminum lake, FD&C Red No. 40 aluminum lake, FD&C Blue No.

1 aluminum lake, D&C Yellow No. 10 aluminum lake, n-butyl alcohol, propylene glycol, SDA-3A alcohol, and titanium dioxide. It is formulated for oral use.

Chemical Structure

💬 Information for Patients 92 words ▾

Information for Patients Advise the patient to read the FDA-approved patient labeling (Medication Guide). Patients should take the drug as prescribed, in the dosage prescribed, and no more frequently than prescribed. Patients should be informed that changes in vision should be reported and evaluated.

Retinal examinations including optical coherence tomography (OCT) and auto-fluorescence imaging are suggested for all patients within six months of starting ELMIRON ® and periodically during long-term treatment (see WARNINGS ). Patients should be reminded that ELMIRON ® has a weak anticoagulant effect. This effect may increase bleeding times.

💬 Medication Guide ~3 min read ▾

This Medication Guide has been approved by the U.S. Food and Drug Administration Revised: 07/2024 MEDICATION GUIDE ELMIRON ® (EL ma ron) (pentosan polysulfate sodium) capsules, for oral use What is the most important information I should know about ELMIRON? Serious side effects have been reported with the use of ELMIRON, including: Changes in the retina of the eye (pigmentary maculopathy).

Taking ELMIRON may be associated with pigment changes in the retina of the eye that may continue even after stopping treatment with ELMIRON. Tell your healthcare provider including your eye doctor right away if you have any vision changes including any of these symptoms: difficulty reading your vision takes longer to adjust to low or reduced light blurred vision Throughout your treatment, regular eye examinations that include retinal examinations are suggested for early detection of retinal/macular changes. Your doctor will discuss with you when to get your first eye examination and follow-up exams, and whether the treatment should be continued.

Increased bleeding. ELMIRON may increase bleeding. Tell your healthcare provider right away if you have any of these symptoms: bruising easily nosebleeds bleeding gums blood in your stool Your risk of bleeding may be increased if you take ELMIRON along with other medicines such as: warfarin sodium heparin high doses of aspirin anti-inflammatory medicines such as ibuprofen Tell your healthcare provider if you are taking any of these medicines.

Before you start taking ELMIRON, tell your healthcare provider if you are going to have surgery. Your healthcare provider may stop ELMIRON before you have surgery. Talk to your healthcare provider about when to stop taking ELMIRON and when to start taking it again.

What is ELMIRON? ELMIRON is a prescription medicine used to treat bladder pain or discomfort associated with interstitial cystitis. It is not known if ELMIRON is safe and effective in children under 16 years of age.

Do not take ELMIRON if you: are allergic to pentosan polysulfate sodium or any of the ingredients in ELMIRON. See the end of this Medication Guide for a complete list of ingredients in ELMIRON. Before your take ELMIRON, tell your healthcare provider about all of your medical conditions, including if you: have a personal or family history of eye problems of the retina. have a history of aneurysms. have problems with easy bleeding (thrombocytopenia). have hemophilia. have gastrointestinal problems such as ulcerations, polyps, or diverticula. have liver problems are pregnant or plan to become pregnant.

ELMIRON should be used during pregnancy only if clearly needed. Tell your healthcare provider if you become pregnant while taking ELMIRON. You and your healthcare provider should decide if you should continue to take ELMIRON. are breastfeeding or plan to breastfeed.

It is not known if ELMIRON passes into your breastmilk. You and your healthcare provider should decide if you will take ELMIRON or breastfeed. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine. How should I take ELMIRON?

Take ELMIRON exactly as your healthcare provider tells you to take it. Take 1 capsule of ELMIRON by mouth 3 times a day with water at least 1 hour before meals or 2 hours after meals. Each capsule contains 100 mg of ELMIRON.

If you take too much ELMIRON, call your healthcare provider right away or go to the nearest emergency room. What are the possible side effects of ELMIRON? Serious side effects have been reported with the use of ELMIRON, including: Changes in the retina of the eye Increased bleeding (See " What is the most important information I should know about ELMIRON? ") The most common side effects of ELMIRON are: hair loss diarrhea nausea stomach pain upset stomach headache rash abn… [Excerpted — this section continues on DailyMed.]

⚠️ Precautions ~3 min read ▾

PRECAUTIONS General ELMIRON ® is a weak anticoagulant (1/15 the activity of heparin). At a daily dose of 300 mg (n=128), rectal hemorrhage was reported as an adverse event in 6.3% of patients. Bleeding complications of ecchymosis, epistaxis, and gum hemorrhage have been reported (see ADVERSE REACTIONS ).

Patients undergoing invasive procedures or having signs/symptoms of underlying coagulopathy or other increased risk of bleeding (due to other therapies such as coumarin anticoagulants, heparin, t-PA, streptokinase, high dose aspirin, or nonsteroidal anti-inflammatory drugs) should be evaluated for hemorrhage. Patients with diseases such as aneurysms, thrombocytopenia, hemophilia, gastrointestinal ulcerations, polyps, or diverticula should be carefully evaluated before starting ELMIRON ® . A similar product that was given subcutaneously, sublingually, or intramuscularly (and not initially metabolized by the liver) is associated with delayed immunoallergic thrombocytopenia with symptoms of thrombosis and hemorrhage.

Caution should be exercised when using ELMIRON ® in patients who have a history of heparin-induced thrombocytopenia. Alopecia is associated with pentosan polysulfate and with heparin products. In clinical trials of ELMIRON ® , alopecia began within the first 4 weeks of treatment.

Ninety-seven percent (97%) of the cases of alopecia reported were alopecia areata, limited to a single area on the scalp. Hepatic Insufficiency ELMIRON ® has not been studied in patients with hepatic insufficiency. Because there is evidence of hepatic contribution to the elimination of ELMIRON ® , hepatic impairment may have an impact on the pharmacokinetics of ELMIRON ® .

Caution should be exercised when using ELMIRON ® in this patient population. Mildly (< 2.5 × normal) elevated transaminase, alkaline phosphatase, γ-glutamyl transpeptidase, and lactic dehydrogenase occurred in 1.2% of patients. The increases usually appeared 3 to 12 months after the start of ELMIRON ® therapy, and were not associated with jaundice or other clinical signs or symptoms.

These abnormalities are usually transient, may remain essentially unchanged, or may rarely progress with continued use. Increases in PTT and PT (< 1% for both) or thrombocytopenia (0.2%) were noted. Information for Patients Advise the patient to read the FDA-approved patient labeling (Medication Guide).

Patients should take the drug as prescribed, in the dosage prescribed, and no more frequently than prescribed. Patients should be informed that changes in vision should be reported and evaluated. Retinal examinations including optical coherence tomography (OCT) and auto-fluorescence imaging are suggested for all patients within six months of starting ELMIRON ® and periodically during long-term treatment (see WARNINGS ).

Patients should be reminded that ELMIRON ® has a weak anticoagulant effect. This effect may increase bleeding times. Laboratory Test Findings Pentosan polysulfate sodium did not affect prothrombin time (PT) or partial thromboplastin time (PTT) up to 1200 mg per day in 24 healthy male subjects treated for 8 days.

Pentosan polysulfate sodium also inhibits the generation of factor Xa in plasma and inhibits thrombin-induced platelet aggregation in human platelet rich plasma ex vivo (see PRECAUTIONS-Hepatic Insufficiency ). Carcinogenicity, Mutagenesis, Impairment of Fertility Long-term carcinogenicity studies of ELMIRON ® in F344/N rats and B6C3F1 mice have been conducted. In these studies, ELMIRON ® was orally administered once daily via gavage, 5 days per week, for up to 2 years.

The dosages administered to mice were 56, 168 or 504 mg/kg. The dosages administered to rats were 14, 42, or 126 mg/kg for males, and 28, 84, or 252 mg/kg for females. The dosages tested were up to 60 times the maximum recommended human dose (MRHD) in rats, and up to 117 times the MRHD in mice, on a mg/kg basis.

The results of these studies in rodents showed no clear evidence of drug-related tumorigenesis… [Excerpted — this section continues on DailyMed.]

🍼 Nursing Mothers 35 words ▾

Nursing Mothers It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when ELMIRON ® is administered to a nursing woman.

🧬 Pharmacokinetics ~2 min read ▾

Pharmacokinetics Absorption In a clinical pharmacology study in which healthy female volunteers received a single oral 300 or 450 mg dose of pentosan polysulfate sodium containing radiolabeled drug as a solution under fasted conditions, maximal levels of plasma radioactivity were seen approximately at a median of 2 hours (range 0.6-120 hours) after dosing. Based on urinary excretion of radioactivity, a mean of approximately 6% of a radiolabeled oral dose of pentosan polysulfate sodium is absorbed and reaches the systemic circulation.

Food Effects: In clinical trials, ELMIRON ® was administered with water 1 hour before or 2 hours after meals; the effect of food on absorption of pentosan polysulfate sodium is not known. Distribution Preclinical studies with parenterally administered radiolabeled pentosan polysulfate sodium showed distribution to the uroepithelium of the genitourinary tract with lesser amounts found in the liver, spleen, lung, skin, periosteum, and bone marrow. Erythrocyte penetration is low in animals.

Metabolism The fraction of pentosan polysulfate sodium that is absorbed is metabolized by partial desulfation in the liver and spleen, and by partial depolymerization in the kidney to a large number of metabolites. Both the desulfation and depolymerization can be saturated with continued dosing. Excretion Following administration of an oral solution of a 300 or 450 mg dose of pentosan polysulfate sodium containing radiolabeled drug to groups of healthy subjects, plasma radioactivity declined with mean half-lives of 27 and 20 hours, respectively.

A large proportion of the orally administered dose of pentosan polysulfate sodium (mean 84% in the 300 mg group and 58% in the 450 mg group) is excreted in feces as unchanged drug. A mean of 6% of an oral dose is excreted in the urine, mostly as desulfated and depolymerized metabolites. Only a small fraction of the administered dose (mean 0.14%) is recovered as intact drug in urine.

Special Populations The pharmacokinetics of pentosan polysulfate sodium has not been studied in geriatric patients or in patients with hepatic or renal impairment. See also PRECAUTIONS-Hepatic Insufficiency . Drug-Drug Interactions In a study in which healthy subjects received pentosan polysulfate sodium 100 mg capsule or placebo every 8 hours for 7 days, and were titrated with warfarin to an INR of 1.4 to 1.8, the pharmacokinetic parameters of R-warfarin and S-warfarin were similar in the absence and presence of pentosan polysulfate sodium.

INR for warfarin + placebo and warfarin + pentosan polysulfate sodium were comparable. See also PRECAUTIONS on the use of ELMIRON ® in patients receiving other therapies with anticoagulant effects.

🧬 Pharmacodynamics 50 words ▾

Pharmacodynamics The mechanism by which pentosan polysulfate sodium achieves its effects in patients is unknown. In preliminary clinical models, pentosan polysulfate sodium adhered to the bladder wall mucosal membrane. The drug may act as a buffer to control cell permeability preventing irritating solutes in the urine from reaching the cells.

🔬 Clinical Studies ~3 min read ▾

CLINICAL TRIALS ELMIRON ® was evaluated in two clinical trials for the relief of pain in patients with chronic interstitial cystitis (IC). All patients met the NIH definition of IC based upon the results of cystoscopy, cytology, and biopsy. One blinded, randomized, placebo-controlled study evaluated 151 patients (145 women, 5 men, 1 unknown) with a mean age of 44 years (range 18 to 81).

Approximately equal numbers of patients received either placebo or ELMIRON ® 100 mg three times a day for 3 months. Clinical improvement in bladder pain was based upon the patient's own assessment. In this study, 28/74 (38%) of patients who received ELMIRON ® and 13/74 (18%) of patients who received placebo showed greater than 50% improvement in bladder pain (p = 0.005).

A second clinical trial, the physician's usage study, was a prospectively designed retrospective analysis of 2499 patients who received ELMIRON ® 300 mg a day without blinding. Of the 2499 patients, 2220 were women, 254 were men, and 25 were of unknown sex. The patients had a mean age of 47 years and 23% were over 60 years of age.

By 3 months, 1307 (52%) of the patients had dropped out or were ineligible for analysis; overall, 1192 (48%) received ELMIRON ® for 3 months; 892 (36%) received ELMIRON ® for 6 months; and 598 (24%) received ELMIRON ® for one year. Patients had unblinded evaluations every 3 months for the patient's rating of overall change in pain in comparison to baseline and for the difference calculated in "pain/discomfort" scores. At baseline, pain/discomfort scores for the original 2499 patients were severe or unbearable in 60%, moderate in 33% and mild or none in 7% of patients.

The extent of the patients' pain improvement is shown in Table 1 . At 3 months, 722/2499 (29%) of the patients originally in the study had pain scores that improved by one or two categories. By 6 months, in the 892 patients who continued taking ELMIRON ® , an additional 116/2499 (5%) of patients had improved pain scores.

After 6 months, the percent of patients who reported the first onset of pain relief was less than 1.5% of patients who originally entered in the study (see Table 2 ). Table 1: Pain Scores in Reference to Baseline in Open Label Physician's Usage Study (N=2499) Trial not designed to detect onset of pain relief Efficacy Parameter 3 months CI = 95% confidence interval 6 months Patient Rating of Overall Change in Pain (Recollection of difference between current pain and baseline pain) 6-point scale: 1 = worse, 2 = no better, 3 = slightly improved, 4 = moderately improved, 5 = greatly improved, 6 = symptom gone N=1161 Median = 3 Mean =

3.44CI: (3.37, 3.51) N=724 Median = 4 Mean =

3.91CI: (3.83, 3.99) Change in Pain/Discomfort Score (Calculated difference in scores at the time point and baseline) 3-point scale: 1 = none or mild, 2 = moderate, 3 = severe or unbearable N=1440 Median = 1 Mean =

0.51CI: (0.45, 0.57) N=904 Median = 1 Mean =

0.66CI: (0.61, 0.71) Table 2: Number (%) of Patients with New Relief of Pain/Discomfort First-time Improvement in pain/discomfort score by 1 or 2 categories in the Open-Label Physician's Usage Study (N=2499) at 3 months Number (%) of patients with improvement of pain/discomfort score at 3 months when compared to baseline (n=1192) at 6 months Number (%) of patients without pain/discomfort improvement at 3 months who had improvement at 6 months (n=892) Considering only the patients who continued treatment 722/1192 (61%) 116/892 (13%) Considering all the patients originally enrolled in the study 722/2499 (29%) 116/2499 (5%)

📄 Carcinogenesis, Mutagenesis, Impairment of Fertility 154 words ▾

Carcinogenicity, Mutagenesis, Impairment of Fertility Long-term carcinogenicity studies of ELMIRON ® in F344/N rats and B6C3F1 mice have been conducted. In these studies, ELMIRON ® was orally administered once daily via gavage, 5 days per week, for up to 2 years. The dosages administered to mice were 56, 168 or 504 mg/kg.

The dosages administered to rats were 14, 42, or 126 mg/kg for males, and 28, 84, or 252 mg/kg for females. The dosages tested were up to 60 times the maximum recommended human dose (MRHD) in rats, and up to 117 times the MRHD in mice, on a mg/kg basis. The results of these studies in rodents showed no clear evidence of drug-related tumorigenesis or carcinogenic risk.

Pentosan polysulfate sodium was not clastogenic or mutagenic when tested in the mouse micronucleus test or the Ames test ( S. typhimurium ). The effect of pentosan polysulfate sodium on spermatogenesis has not been investigated.

📄 Package Label / Principal Display Panel 43 words ▾

PRINCIPAL DISPLAY PANEL - 100 mg Capsule Bottle Label NDC 50458-098-01 ELMIRON ® (pentosan polysulfate sodium) CAPSULES 100 mg Attention: Dispense the enclosed Medication Guide to each patient. Each capsule contains 100 mg pentosan polysulfate sodium. Rx only 100 Capsules janssen Elmiron 100mg

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q1 2026 · 5 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
10.3K
Units reimbursed last 4 qtrs
992.1K
Gross reimbursed last 4 qtrs
$11.52M
Avg / prescription
$1,115.36
Avg / unit
$11.6103
Latest quarter Q1 2026
2.3KRx
Medicaid pays / ea
$11.6103
gross reimbursed
vs
NADAC / ea
$12.0883
acquisition cost
=
Spread
−$0.4780
-4% vs cost
What Medicaid paid per ea (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
48% FFS 52% MCO
Fee-for-service · 4,926 Rx Managed care · 5,401 Rx
State Medicaid map
Alaska: no data reported AK Maine: 7,475 units · 536 per 100k residents ME Washington: 15,290 units · 196 per 100k residents WA Idaho: 5,520 units · 281 per 100k residents ID Montana: 4,108 units · 363 per 100k residents MT North Dakota: no data reported ND Minnesota: 8,560 units · 149 per 100k residents MN Wisconsin: 8,952 units · 151 per 100k residents WI Michigan: 31,215 units · 311 per 100k residents MI New York: 65,271 units · 334 per 100k residents NY Vermont: 7,686 units · 1,188 per 100k residents VT New Hampshire: no data reported NH Oregon: 10,451 units · 247 per 100k residents OR Nevada: 4,720 units · 148 per 100k residents NV Wyoming: no data reported WY South Dakota: 2,190 units · 238 per 100k residents SD Iowa: 9,190 units · 287 per 100k residents IA Illinois: 14,469 units · 115 per 100k residents IL Indiana: 17,274 units · 252 per 100k residents IN Ohio: 39,945 units · 339 per 100k residents OH Pennsylvania: 47,287 units · 365 per 100k residents PA New Jersey: 21,354 units · 230 per 100k residents NJ Massachusetts: 19,657 units · 281 per 100k residents MA California: 284,028 units · 729 per 100k residents CA Utah: no data reported UT Colorado: 22,910 units · 390 per 100k residents CO Nebraska: 5,560 units · 281 per 100k residents NE Missouri: 26,200 units · 423 per 100k residents MO Kentucky: 44,511 units · 983 per 100k residents KY West Virginia: 24,948 units · 1,409 per 100k residents WV Virginia: 10,857 units · 125 per 100k residents VA Maryland: 9,873 units · 160 per 100k residents MD Connecticut: 10,329 units · 286 per 100k residents CT Rhode Island: no data reported RI Arizona: 9,180 units · 124 per 100k residents AZ New Mexico: no data reported NM Kansas: 1,020 units · 34.7 per 100k residents KS Arkansas: 2,685 units · 87.5 per 100k residents AR Tennessee: 20,100 units · 282 per 100k residents TN North Carolina: 33,050 units · 305 per 100k residents NC South Carolina: 4,256 units · 79.2 per 100k residents SC Delaware: 1,050 units · 102 per 100k residents DE Oklahoma: 6,574 units · 162 per 100k residents OK Louisiana: 26,242 units · 574 per 100k residents LA Mississippi: no data reported MS Alabama: 5,550 units · 109 per 100k residents AL Georgia: 10,972 units · 99.5 per 100k residents GA D.C.: no data reported DC Hawaii: no data reported HI Texas: 25,600 units · 83.9 per 100k residents TX Florida: 10,595 units · 46.9 per 100k residents FL
Units reimbursed · per 100k residents
34.71,409
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 West Virginia 1,409 /100k
2 Vermont 1,188 /100k
3 Kentucky 983 /100k
4 California 729 /100k
5 Louisiana 574 /100k
6 Maine 536 /100k
7 Missouri 423 /100k
8 Colorado 390 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Elmiron — the program that covers self-administered drugs. 1 manufacturer.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Elmiron. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$10.57M
Claims incl. refills
8.4K
Beneficiaries
4.9K
Spend / beneficiary
$2,169.91
Spend / claim
$1,263.36
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.

Reported adverse events (FAERS)

Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for ELMIRON (this brand).

Top reported reactions

Maculopathy1,398
Retinal Pigmentation607
Dry Age-related Macular Degeneration562
Pigmentary Maculopathy470
Pain304
Nausea278
Headache237

Age at onset

Neonate3
Infant1
Child3
Adolescent11
Adult2,365
Elderly760

Reporter sex

6,930 reports
Male · 9%
Female · 90%
Unknown · 0%

Serious outcomes

Hospitalization653
Disabling143
Death120
Life-threatening79
Reports over time (by year) — tap or hover for the count & year
2019 2021 2023 2026 1,541 94
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.